Ultragenyx Pharmaceutical Inc (RARE) Receives Average Recommendation of “Buy” from Brokerages

Shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) have received a consensus recommendation of “Buy” from the sixteen analysts that are covering the firm. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $85.64.

Several brokerages have weighed in on RARE. Piper Jaffray Companies cut shares of Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $96.00 to $70.00 in a research report on Wednesday, March 22nd. Wedbush lowered shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $80.00 to $75.00 in a report on Wednesday, April 19th. HC Wainwright lowered shares of Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $88.00 to $72.00 in a report on Wednesday, April 19th. SunTrust Banks, Inc. upped their price objective on shares of Ultragenyx Pharmaceutical from $100.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, April 19th. Finally, Canaccord Genuity restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Monday, May 8th.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down 2.61% during trading on Tuesday, reaching $57.47. 286,129 shares of the company were exchanged. The stock’s 50-day moving average is $60.91 and its 200-day moving average is $71.55. The firm’s market cap is $2.43 billion. Ultragenyx Pharmaceutical has a 52-week low of $46.52 and a 52-week high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.71) by $0.08. During the same quarter in the previous year, the firm posted ($1.35) EPS. Equities research analysts predict that Ultragenyx Pharmaceutical will post ($7.02) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Ultragenyx Pharmaceutical Inc (RARE) Receives Average Recommendation of “Buy” from Brokerages” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2017/05/20/brokerages-set-ultragenyx-pharmaceutical-inc-rare-price-target-at-87-36-updated-updated.html.

In related news, insider Theodore Alan Huizenga sold 2,500 shares of the stock in a transaction dated Thursday, March 9th. The shares were sold at an average price of $86.34, for a total transaction of $215,850.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Shalini Sharp sold 12,000 shares of the stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $80.14, for a total transaction of $961,680.00. Following the sale, the chief financial officer now directly owns 63,887 shares in the company, valued at $5,119,904.18. The disclosure for this sale can be found here. Over the last quarter, insiders sold 26,500 shares of company stock valued at $2,258,730. 10.10% of the stock is owned by company insiders.

A number of hedge funds have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 3.7% in the first quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 115 shares during the period. Pacer Advisors Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 9.4% in the third quarter. Pacer Advisors Inc. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 192 shares during the period. Prudential Financial Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 5.8% in the first quarter. Prudential Financial Inc. now owns 3,660 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 200 shares during the period. Amalgamated Bank increased its stake in shares of Ultragenyx Pharmaceutical by 4.6% in the first quarter. Amalgamated Bank now owns 4,628 shares of the biopharmaceutical company’s stock valued at $314,000 after buying an additional 202 shares during the period. Finally, BlackRock Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 6.8% in the third quarter. BlackRock Inc. now owns 4,244 shares of the biopharmaceutical company’s stock valued at $301,000 after buying an additional 271 shares during the period. 96.35% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

12 Month Chart for NASDAQ:RARE

Receive News & Ratings for Ultragenyx Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply